SynAct Pharma AB (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, today announces CEO Jeppe Øvlesen, CSO Thomas Jonassen and CBO Jim Knight participate in the J.P. Morgan Healthcare Conference January 13-16 in San Francisco.
“This is a great opportunity for us to talk to continue our discussions with a wide range of potential partners and investors about the ongoing Phase 2b ADVANCE study in newly diagnosed severe rheumatoid arthritis (RA) patients with the lead compound resomelagon (AP1189),” said CEO Jeppe Øvlesen. “This conference will help us kick start what we expect to be an exciting 2025 within business development.”